Regional therapies for in-transit disease

Paul J. Speicher; Claire H. Meriwether; Douglas S. Tyler

doi:10.1016/j.soc.2014.12.008

Regional therapies for in-transit disease

Paul J. Speicher, Claire H. Meriwether, Douglas S. Tyler

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

Original language	English (US)
Pages (from-to)	309-322
Number of pages	14
Journal	Surgical Oncology Clinics of North America
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/j.soc.2014.12.008
State	Published - Apr 1 2015
Externally published	Yes

Keywords

In-transit melanoma
Isolated limb infusion
Isolated limb perfusion
Regional therapy

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2014.12.008

Cite this

@article{89bb514a20d5445a93a482bc1fbe5757,

title = "Regional therapies for in-transit disease",

abstract = "In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.",

keywords = "In-transit melanoma, Isolated limb infusion, Isolated limb perfusion, Regional therapy",

author = "Speicher, {Paul J.} and Meriwether, {Claire H.} and Tyler, {Douglas S.}",

note = "Publisher Copyright: {\textcopyright} 2015.",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.soc.2014.12.008",

language = "English (US)",

volume = "24",

pages = "309--322",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Regional therapies for in-transit disease

AU - Speicher, Paul J.

AU - Meriwether, Claire H.

AU - Tyler, Douglas S.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

AB - In-transit melanoma is an uncommon pattern of recurrence, but presents unique management challenges and opportunities for treatment. The clinical presentation usually involves from 1 to more than 100 small subcutaneous or cutaneous nodules, ranging from submillimeter to multiple centimeters in diameter. Regional chemotherapy techniques are a mainstay of treatment of patients without systemic disease spread. Future applications of regional therapy are likely to involve combination therapy with cytotoxic agents and novel immune modulators. Regional therapy provides distinct opportunities for the treatment of unresectable disease, and offers a unique platform for investigation of novel therapeutics in early-stage clinical trials.

KW - In-transit melanoma

KW - Isolated limb infusion

KW - Isolated limb perfusion

KW - Regional therapy

UR - http://www.scopus.com/inward/record.url?scp=84926124227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926124227&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2014.12.008

DO - 10.1016/j.soc.2014.12.008

M3 - Review article

C2 - 25769714

AN - SCOPUS:84926124227

SN - 1055-3207

VL - 24

SP - 309

EP - 322

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 2

ER -

Regional therapies for in-transit disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this